Part I: Market Architecture and the Valuation Problem Why the Headlines Are Misleading The Latin American generic drug market will […]

Section 1: What Biosimilar Cost-Effectiveness Actually Measures The Misread Metric Most coverage of biosimilars collapses cost-effectiveness into a single question:

Somewhere in a regulatory affairs department right now, a development team is arguing about whether to run a comparative clinical

There is a certain type of pharmaceutical executive who still thinks of patent searching as something lawyers do—a back-office function

Generic drug approval is, at its core, a race with rules. The company that reads the rules fastest and most

Biosimilar-to-Biosimilar Switching: The Complete IP, Clinical, and Market Playbook For pharma IP teams, portfolio managers, R&D leads, and institutional investors

The 55% figure should stop every pharma IP team in its tracks. That is the share of new small-molecule drugs

Generic drug development has never been a solo endeavor, but the industry has spent the last decade pretending otherwise. Companies

The average generic drug program takes 3 to 4 years from target identification to FDA approval. For most companies, that